Shares of Puma Biotechnology (NASDAQ:PBYI) rocketed Friday after the biopharmaceutical company beat Wall Street’s fourth-quarter estimates thanks to sales of its flagship breast cancer drug Nerlynx (neratinib).
In its latest reporting period, the Los Angeles company’s net loss shrank to $12.2 million, or $0.32 per share, from a loss of $38.6 million, or $1.03 per share, in the year-ago quarter. Its sales amounted to $71.1 million, of which $61.1 million was revenue from Nerlynx and $10 million was license revenue.
Investors were impressed by the results, sending Puma shares up 28% to $35.60 in pre-market action before Friday’s opening bell.
READ: Puma Biotechnology’s 3Q earnings beat Street, but stock plummets as sale of cancer drug Nerlynx slows
Analysts had expected Puma to lose $0.69 and post revenue of $53.65 million.
Puma won approval from the US Food and Drug Administration for Nerlynx which treats early-stage HER2-positive breast cancer, in July of 2017. The drug has also been granted marketing authorization to treat early-stage breast cancer by the European Commission.
Contact Ellen [email protected]